Trial · NCT07901348
GENIVS Block Versus Adductor Canal Block After Total Knee Arthroplasty
NCT07901348, Not applicable, Not yet recruiting, Bakirkoy Dr. Sadi Konuk Research and Training Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GENIVS Block Versus Adductor Canal Block After Total Knee Arthroplasty. Trials, record NCT07901348. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901348
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GENIVS Block Versus Adductor Canal Block After Total Knee Arthroplasty
- NCT number
- NCT07901348
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 74 participants, estimated
- Lead sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
- Conditions
- Arthroplasty, Replacement, Knee, Pain, Postoperative, Osteoarthritis, Knee
- Interventions
- GENIVS block, Adductor Canal Block (ACB) Only
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total opioid consumption in the first 24 hours | 0 to 24 hours after PCA connection | Total opioid consumption, measured as the cumulative intravenous tramadol dose (mg) recorded by the patient-controlled analgesia device from PCA connection (hour 0) to 24 hours. |
| Secondary | Pain at rest | 2, 4, 8, 12 and 24 hours after PCA connection | Pain at rest on a 10-cm visual analog scale (0 = no pain, 10 = worst imaginable pain). |
| Secondary | Pain during active knee flexion | 2, 4, 8, 12 and 24 hours after PCA connection | Pain during active knee flexion on a 10-cm visual analog scale (0 = no pain, 10 = worst imaginable pain), measured after the spinal motor block has resolved (Bromage score 1). |
| Secondary | Time to first analgesic request | Up to 24 hours after PCA connection | Time (hours) from PCA connection to the first bolus request on the patient-controlled analgesia device. |
| Secondary | Rescue analgesic requirement | 0 to 24 hours after PCA connection | Proportion of patients who receive rescue intravenous dexketoprofen (given when the VAS score at rest is 4 or higher) and the number of rescue doses. |
| Secondary | Timed Up and Go test | 24, 48 and 72 hours after PCA connection | Time (seconds) to rise from a standard armchair, walk 3 meters, turn, walk back and sit down, performed with a walker under physiotherapist supervision. The proportion of patients unable to complete the test is also reported. |
| Secondary | Stair climbing performance | Postoperative day 2 | Number of steps climbed in a single attempt without stopping on a standard staircase (step height about 17 cm, one handrail), under physiotherapist supervision. |
| Secondary | Quality of recovery | 24 hours after PCA connection | Total score of the Turkish version of the Quality of Recovery-15 questionnaire (range 0-150; higher scores indicate better recovery). |
| Other | Late pain scores | 36, 48, 60 and 72 hours after PCA connection | Pain at rest and during active knee flexion on a 10-cm visual analog scale (0 = no pain, 10 = worst imaginable pain). |
| Other | Late opioid consumption | 24 to 48 hours and 48 to 72 hours after PCA connection | Intravenous tramadol consumption (mg) recorded by the patient-controlled analgesia device. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07901348
GET https://conductscience.org/api/trials/v1/NCT07901348/registered